AutoImmune Inc. is a biopharmaceutical company developing products to treat autoimmune and other cell-mediated inflammatory conditions. Several of these products are based on a biological mechanism known as oral tolerance, which provides tissue specific immunosuppression without toxicity or significant side effects.

Ore Pharmaceuticals Inc. company was founded in 1994 and is headquartered in Cambridge, Massachusetts. Ore Pharmaceutical Holdings Inc., through its wholly owned subsidiary, Ore Pharmaceuticals Inc., operates as a drug development company in the United States. Its drug candidates include GL1001, the lead drug candidate that completed a multiple ascending dose Phase I clinical trial, for the treatment of inflammatory bowel disease; tiapamil for treatment of diseases of central nervous system, primarily focused on cognition and memory; and romazarit, a clinical-stage drug candidate for the treatment of metabolic indications, such as obesity.

Proteome Sciences plc is a United Kingdom-based company. The Company is principally engaged in biomarker research and development primarily in the field of applied proteomics, using techniques to detect and characterize differentially expressed proteins in diseases for diagnostic, prognostic and therapeutic applications. Through its ProteoSHOP toolkit, Proteome Sciences provides proteomics solutions, including traditional two dimensional gel-based electrophoresis (2DE) and gel-free protein sequence tag technologies (PST, qPST& TMT), to pharma, biotechnology and diagnostic companies. The Company has research facilities in London, the United Kingdom and Frankfurt, Germany. Its subsidiaries include Proteome Sciences R&D Verwaltungs GmbH, Proteome Sciences R&D GmbH & Co. KG, Xzillion GmbH & Co. KG, Proteome Sciences, Inc., Veri-Q Inc., Phenomics Limited and Electrophoretics Limited.

Medpace is on pace to bring new drugs to market. The contract research organization (CRO) offers clinical trial management and regulatory consulting to pharmaceutical and biotech companies that are developing new drug candidates in the areas of cardiology, metabolism, and oncology. Its services include clinical development planning, data management, laboratory services, quality assurance auditing, regulatory document preparation, safety surveillance, and statistical analysis. Its Web-based ClinTrak tool allows users to access and track real-time clinical study data and metrics. Medpace serves customers worldwide through offices in Africa, the Americas, Asia, Australia, Europe, and the Middle East.

Omega Diagnostics Group PLC is a United Kingdom-based holding company. The Company, along with its subsidiaries, is principally engaged in the manufacture, development and distribution of medical diagnostic products. The Company sells a range of products, primarily in the immunoassay, in-vitro diagnostics (IVD) market, through a distribution network in over 100 countries. The Company operates in a niche market in supplying tests for specific infectious diseases, autoimmune disease and food tolerance. The Company subsidiaries include Investment in Omega Diagnostics Limited, Investment in Genesis Diagnostics Limited, Investment in Cambridge Nutritional Sciences Limited, Investment in Bealaw (692) Limited and Investment in Bealaw (693) Limited.

ARIAD Pharmaceuticals, Inc. company was founded in 1991 and is based in Cambridge, Massachusetts. ARIAD Pharmaceuticals, Inc. (ARIAD) is a biopharmaceutical company engaged in the discovery and development of medicines to treat cancers by regulating cell signaling with small molecules. The Company’s lead cancer product candidate, deforolimus, is an internally discovered, potent inhibitor of the protein mTOR, a master switch in cancer cells. Blocking mTOR creates a starvation-like effect in cancer cells by interfering with cell growth, division, metabolism and angiogenesis. Its second product candidate, AP24534, is a multi-targeted kinase inhibitor that has potential applications in cancer and is wholly owned by the Company. The company also focused drug discovery program centered on small-molecule therapies, molecularly targeted to cell-signaling pathways implicated in cancer. It also developed a portfolio of cell-signaling regulation technologies, its ARGENT technology, to control intracellular processes with small molecules.

When new drugs are tested, someone has to go first and Chiltern (Early Phase) Ltd. (formerly Drug Development Solutions) will help find that person. A contract research organization (CRO), the company specializes in bridging the gap between preclinical studies and the early stages of clinical trials in humans for drug candidates. Its clients include large multinational companies as well as small biotech startups. The company's facilities are based inside a major hospital with access to emergency medical care if needed. The company was spun off from the University of Dundee in 1982 and then acquired by CRO giant Chiltern International in 2008.

Aradigm Corporation company was founded in 1991 and is based in Hayward, California. Aradigm Corporation, a pharmaceutical company, engages in the development and commercialization of drugs delivered by inhalation for the treatment of respiratory diseases by pulmonologists in the United States. Aradigm company's activities include partnered and self-initiated development programs addressing the treatment of cystic fibrosis, bronchiectasis, pulmonary arterial hypertension, chronic obstructive pulmonary disease (COPD), inhalation anthrax infections, and smoking cessation. Its proprietary product candidates under development include ARD-3100 under phase II clinical trial for the treatment of cystic fibrosis; ARD-3150 under phase II clinical trial for the treatment of bronchiectasis; ARD-1600 under phase I clinical trial for the treatment of tobacco smoking cessation; and ARD-1100, a preclinical product for the treatment of inhalation anthrax indications. Aradigm company's collaborative product candidates comprise ARD-1550, a phase II product and ARD-1500, a preclinical stage product for the treatment of pulmonary arterial hypertension; and ARD-1700, a preclinical stage product for the treatment of asthma and COPD. Aradigm Corporation has a collaboration agreement with CyDex Pharmaceuticals, Inc. for the development and commercialization of products to deliver inhaled corticosteroids, anticholinergics, and beta-2 agonists for the treatment of asthma and COPD.

CytRx Corporation company was founded in 1985 and is headquartered in Los Angeles, California. CytRx Corporation, a biopharmaceutical research and development company, engages in the development of human therapeutics. Its product pipeline includes Tamibarotene, a synthetic retinoid in Phase II clinical development to treat acute promyelocytic leukemia; INNO-2006, a pro-drug for doxorubicin in Phase II clinical development for the treatment of cancer; Bafetinib, a drug in Phase I clinical development to treat chronic myeloid leukemia; Arimoclomol, an orally-administered small-molecule product candidate in Phase IIb clinical development for the treatment of amyotrophic lateral sclerosis; and Iroxanadine, an orally-administered small-molecule product candidate in Phase I clinical development to treat diabetic ulcers. The company also engages in developing treatments for neurodegenerative and other disorders based on its small-molecule molecular chaperone amplification technology; and new-drug discovery research utilizing its master chaperone regulator assay technology.

Dow Pharmaceutical Sciences company researches and develops topical dermatological pharmaceutical and biotech products for external clients. It works to formulate the gel, ointment, or cream that will carry a client's drug, assesses its effectiveness, manufactures and packages product candidates for clinical trials, and provides regulatory affairs consulting. It provides contract research services through its Solano Clinical Research division in the US and its Bioskin subsidiary in Europe. Dow Pharmaceutical Sciences also develops dermatology products on a proprietary basis. The company is owned by Valeant Pharmaceuticals.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.